ESLICARBAZEPINE ACETATE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ESLICARBAZEPINE ACETATE (ESLICARBAZEPINE ACETATE).
Eslicarbazepine acetate is a voltage-gated sodium channel blocker that stabilizes the inactive state of sodium channels, reducing high-frequency repetitive firing of neurons. It also modulates T-type calcium channels and enhances slow inactivation of sodium channels.
| Metabolism | Eslicarbazepine acetate is rapidly hydrolyzed by esterases in the liver and blood to the active metabolite eslicarbazepine. Eslicarbazepine is further metabolized via glucuronidation (UGT1A4, UGT1A9, UGT2B7) and, to a minor extent, by CYP3A4 oxidation. |
| Excretion | Renal: ~90% (as glucuronide conjugates and unchanged drug; ~30% as eslicarbazepine acetate, ~60% as eslicarbazepine). Fecal: <1%. Biliary: negligible. |
| Half-life | Terminal half-life of eslicarbazepine is 13-20 hours (mean ~14 hours), supporting once-daily dosing. |
| Protein binding | Eslicarbazepine acetate: ~40% bound to plasma proteins (primarily albumin); eslicarbazepine: ~30% bound. |
| Volume of Distribution | Eslicarbazepine: Vd/F ~2.5 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Oral: At least 80% (absolute bioavailability due to extensive first-pass metabolism; eslicarbazepine acetate is a prodrug rapidly converted to eslicarbazepine). |
| Onset of Action | Oral: Time to peak plasma concentration (Tmax) is 1-4 hours; clinical effect (seizure reduction) typically observed within 1-2 weeks of starting therapy. |
| Duration of Action | Oral: Duration of antiepileptic effect corresponds to dosing interval (24 hours with once-daily dosing); steady-state achieved within 4-5 days. |
400 mg orally once daily, titrated to a maintenance dose of 800-1200 mg once daily.
| Dosage form | TABLET |
| Renal impairment | CrCl >30 mL/min: no adjustment. CrCl 15-30 mL/min: reduce dose by 50% (max 600 mg/day). CrCl <15 mL/min: not recommended. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50% (max 600 mg/day). Child-Pugh C: not recommended. |
| Pediatric use | Not established; off-label doses range from 20-40 mg/kg/day divided twice daily, but no FDA approved pediatric dosing. |
| Geriatric use | Start at 200 mg daily; consider lower titration due to decreased renal function; monitor for hyponatremia and dizziness. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ESLICARBAZEPINE ACETATE (ESLICARBAZEPINE ACETATE).
| Breastfeeding | Eslicarbazepine is excreted into human breast milk. The milk-to-plasma (M/P) ratio is approximately 1.4, indicating significant transfer. Infant serum levels are estimated to be 12-20% of maternal therapeutic levels. Limited data suggest no acute adverse effects, but prolonged exposure could affect infant neurodevelopment. Breastfeeding is generally not recommended unless benefits outweigh risks, and infant monitoring for sedation, poor feeding, and weight loss is advised. |
| Teratogenic Risk | Eslicarbazepine acetate is associated with an increased risk of major congenital malformations, particularly neural tube defects, craniofacial defects, and cardiovascular malformations, when used during the first trimester. In the second and third trimesters, exposure may be associated with adverse neurodevelopmental outcomes and growth restriction. Data are derived from studies on eslicarbazepine and the related compound oxcarbazepine, as eslicarbazepine is the active metabolite. Risk is dose-dependent and higher with polytherapy. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to eslicarbazepine acetate or any component of the formulation; history of hypersensitivity reactions to carbamazepine or oxcarbazepine (cross-sensitivity); severe hepatic impairment (Child-Pugh C); second- or third-degree atrioventricular block without pacemaker (due to PR interval prolongation).
| Precautions | Hyponatremia (sodium <125 mmol/L), particularly in elderly or patients on diuretics; suicidal thoughts and behavior; dizziness and somnolence; ataxia and gait disturbance; multiorgan hypersensitivity reactions; hematologic abnormalities (leukopenia, thrombocytopenia); liver enzyme elevations; withdrawal seizures upon abrupt discontinuation; teratogenicity (pregnancy category C); drug interactions (especially with carbamazepine, phenytoin, and oral contraceptives). |
Loading safety data…
| Fetal Monitoring | Monitor maternal eslicarbazepine trough levels monthly during pregnancy and postpartum due to altered pharmacokinetics. Perform fetal ultrasound at 18-20 weeks gestation to screen for structural anomalies. Assess fetal growth by serial ultrasound in third trimester. Monitor maternal for signs of toxicity (e.g., dizziness, ataxia, diplopia) and adjust dose as needed. Postnatally, monitor infant for withdrawal symptoms (e.g., irritability, feeding difficulties, jitteriness) and ensure blood clotting studies (vitamin K-dependent) are normal. |
| Fertility Effects | Eslicarbazepine acetate may reduce efficacy of hormonal contraceptives due to enzyme induction (CYP3A4), potentially affecting fertility planning. There is no direct evidence of impairment of fertility in humans; animal studies show no significant effects on male or female fertility at clinically relevant doses. However, polytherapy with enzyme-inducing antiepileptics may exacerbate effects on hormonal contraceptives. |